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Dear Sir,
It was with significant interest that we read the manu-
script, entitled‘‘Serum Levels of Infliximab and Anti-Inflixi-
mab Antibodies in Brazilian Patients with Crohn’s Disease’’,
recently published in this distinguished journal by Gomes
et al. (1). In this study, the authors measured the serum infli-
ximab (IFX) levels of 40 patients with Crohn’s disease (CD)
and correlated their findings with disease activity. There was
no difference in the IFX level between patients with active
disease and those with remission (po0.05). Surprisingly,
eighty percent of all patients had IFX levels above the thera-
peutic concentration (6-10 mg/mL).
Despite this cross-sectional study bringing interesting find-
ings to the Brazilian literature, some important issues need to
be explored. The therapeutic window considered by Gomes
et al. was 6-10 mg/ml, which is different from what is consi-
dered globally, despite different assays being used worldwide.
The TAXIT trial, one of the first prospective studies in the
field, considered a therapeutic level of IFX for CD to be between
3 and 7 mg/mL (2). In an Australian consensus on thera-
peutic drug monitoring for CD, the therapeutic level for IFX
was considered between 3 and 8 mg/mL (3). The definition
considered by Gomes et al. might have mixed the results
of the study, as several patients had levels from 3-6 mg/mL,
which are considered adequate according to most studies but
would be considered infra-therapeutic levels in the study
from Campinas. If that remains an assay manufacturer’s
standard, this still needs clarification.
Even more surprising is the finding that the absolute
majority of patients under IFX therapy in the study had supra-
therapeutic levels (above 10 mg/mL). There have been 3
Brazilian manuscripts published to date regarding the serum
infliximab levels in inflammatory bowel disease. The three
studies considered a therapeutic IFX level of 3-7 mg/mL. The
proportion of patients with supra-therapeutic levels was
17.46% according to Kampa et al. in a study using ELISA kits
that were shipped and analyzed in Leuven, Belgium, which
also included UC patients (4). Similar supra-therapeutic levels
were found by Parra et al. (11.3%) in a study using the
Quantum Blue rapid test (5). In another multicentric study,
similar proportions were also found (8.16% with a different
ELISA assay and 16.33% with the Quantum Blue rapid test)
(6). The percentage of supra-therapeutic levels found by Gomes
et al. (80% of the sample), even considering the upper limit of
10 mg/mL, is extremely high and not compatible with other
studies from the same country. Most likely, different regimens
of dose optimization or intrinsic differences among the different
assays used could explain these findings, but that deserves
clarification.
Another important point raised in the present study was
that there was no difference in the serum level between
patients with active disease and those in remission. This also
goes in the opposite direction of the literature, which clearly
demonstrates that higher levels of IFX are associated with
higher rates of clinical, endoscopic and even histological
remission (7). Possible reasons for the absence of a difference
between the active and remission groups could be linked to
the definition of disease activity, despite the authors using
endoscopic and imaging tests to define remission.
The differences between the study by Gomes et al. and the
national literature in this topic once more demonstrates the
controversy that exists regarding therapeutic drug monitor-
ing in the management of CD. Serum levels may vary
according to assays, severity of the disease, albumin levels
and other individual characteristics that are not yet known.
Therefore, one should be careful in using serum levels as a
single tool to optimize therapeutic management with IFX,
by increasing doses, reducing intervals or even stopping
therapy. A whole clinical picture of the patient needs to be
considered before significant changes are made in practice.
’ REFERENCES
1. Gomes LEM, da Silva FAR, Pascoal LB, Ricci RL, Nogueira G, Camargo
MG, et al. Serum Levels of Infliximab and Anti-Infliximab Antibodies in
Brazilian Patients with Crohn ’ s Disease. Clinics. 2019;74:e824. https://
doi.org/10.6061/clinics/2019/e824
2. Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G,
Van Steen K, et al. Trough concentrations of Infliximab guide dosing for
patients with inflammatory bowel disease. Gastroenterology. 2015;148
(7):1320–9.e3. https://doi.org/10.1053/j.gastro.2015.02.031
3. Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore
GT, et al. Review article: consensus statements on therapeutic drug
monitoring of anti-tumour necrosis factor therapy in inflammatory bowel
diseases. Aliment Pharmacol Ther. 2017;46(11-12):1037–53. https://doi.
org/10.1111/apt.14368DOI: 10.6061/clinics/2019/e1424
Copyright & 2019 CLINICS – This is an Open Access article distributed under the
terms of the Creative Commons License (http://creativecommons.org/licenses/by/
4.0/) which permits unrestricted use, distribution, and reproduction in any
medium or format, provided the original work is properly cited.
No potential conflict of interest was reported.
1
COMMENTS
4. Kampa KC, Morsoletto DBG, Loures MR, Pissaia A, Nones RB, Ivantes
CAP. Importance of measuring levels of Infliximab in patients treat-
ing inflammatory bowel disease in a Brazilian cohort. Arq Gastro-
enterol. 2017;54(4):333–7. https://doi.org/10.1590/s0004-2803.2017000
00-41
5. Parra RS, Feitosa MR, Ribeiro LCH, Castro LA, Rocha JJR, Féres O.
Infliximab Trough Levels and Quality of Life in Patients with Inflamma-
tory Bowel Disease in Maintenance Therapy. Gastroenterol Res Pract.
2018;2018:1952086. https://doi.org/10.1155/2018/1952086
6. Teixeira FV, Sassaki LY, Saad-Hossne R, Baima JP, Magro DO, Coy CSR,
et al. Serum Infliximab measurement in inflammatory bowel disease
patients in remission: a comparative analysis of two different methods in
a multicentric Brazilian cohort. Arq Gastroenterol. 2018;55(2):192–7.
https://doi.org/10.1590/s0004-2803.201800000-35
7. Honap S, Cunningham G, Tamilarasan AG, Irving PM. Positioning bio-
logics and new therapies in the management of inflammatory bowel
disease. Curr Opin Gastroenterol. 2019. https://doi.org/10.1097/MOG.
0000000000000546. [Epub ahead of print]
2
Serum levels of infliximab in Brazilian patients
Teixeira FV et al.
CLINICS 2019;74:e1424
